View Older Stories View More Recent Stories
-
Form 4 Ra Pharmaceuticals, Inc. For: Nov 01 Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G Eiger BioPharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
-
PlacementTracker Publishes Q3 2018 Private Placement Market League Tables
-
Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 3 ARVINAS HOLDING COMPANY, For: Sep 26 Filed by: RA CAPITAL MANAGEMENT, LLC
-
Lyra Therapeutics Announces $29.5 Million Series B Financing to Advance Innovative Therapeutics for Ear, Nose and Throat Diseases
-
The Arizona Bioscience Company of the Year is on a Mission to Cure the Uncurable
-
TeraPore Technologies Unveils New Nanofiltration Membrane Technology at BioProcess International Conference
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Ivantis Announces FDA Approval for Its Innovative Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery (MIGS)
-
Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline
-
Akouos Raises $50 Million Series A Financing and Expands Team to Advance Precision Genetic Therapies That Restore and Preserve Hearing
-
Form SC 13G/A BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, LLC
-
Biopharmaceutical Industry Veteran Marty Siwak joins TeraPore Technologies as Chief Commercial Officer
-
PlacementTracker Publishes First Half 2018 PIPE Market League Tables
-
Mitra RxDx Announces $40 Million Financing Round
-
Form SC 13G/A SUNESIS PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13D Eidos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs
-
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
-
Form 3 Eidos Therapeutics, Inc. For: Jun 19 Filed by: RA CAPITAL MANAGEMENT, LLC
-
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines
-
Form SC 13G/A InflaRx N.V. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial
-
New Data from the HORIZON Trial of the Hydrus® Microstent Shows Significantly Lower IOP and Medication Use at 24 Months in a US Patient Cohort
-
Eidos Therapeutics completes $64M Series B financing
-
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
-
Form SC 13D BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, LLC
-
RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals
-
RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals
-
InflaRx Full Year 2017 Financial & Operating Results
-
Form SC 13D/A Dicerna Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
The Economist Events Presents: "Healthcare Forum 2018: Financing Healthcare Innovation"
-
TeraPore Technologies Raises $6M in Oversubscribed Series A Funding Round
-
Form SC 13D/A Ra Pharmaceuticals, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A AQUINOX PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G ENDOCYTE INC Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G Spero Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13D Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G PROTEON THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A ARCA biopharma, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G Kadmon Holdings, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G Krystal Biotech, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A AveXis, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Strongbridge Biopharma Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A ACHILLION PHARMACEUTICAL Filed by: RA CAPITAL MANAGEMENT, LLC

